JAK1/JAK2 inhibitor — first JAK inhibitor approved (2011). Indications: myelofibrosis, polycythemia vera (HU-resistant), steroid-refractory acute + chronic GVHD. CYP3A4 substrate. Discontinuation of ruxolitinib in MF requires a slow taper to avoid cytokine-rebound systemic inflammatory response. PK (Jakafi label, 20 mg PO bid IR): Cmax 205-7100 nM across single-dose range (linear), Tmax 1-2 h, F ≥95%, t½ 3.0 h IR formulation (5.4 h newer ER once-daily formulation), Vss 72 L. CYP3A4 substrate; no significant food effect.
Half-Life & Elimination Curve (PO: 3h)
Plasma (PO)t½ Decay (3h)
0×t½0h100%(0.17 mg/L)
1×t½3h50%(85 µg/L)
2×t½6h25%(42.5 µg/L)
3×t½9h12.5%(21.2 µg/L)
4×t½12h6.3%(10.6 µg/L)
5×t½15h3.1%(5.31 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.91h
Est. Peak (Cmax)0.17 mg/L
Clearance (CL)16.6 L/h
97% Washout (5×t½)15h
Dosing Guidelines
Oral (PO): Typical 20 mg (Range: 5–50 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 95% · Volume of Distribution (Vd): 72 L · Absorption (ka): 1 h⁻¹ (t½ka ≈ 42m) [PMID 37000342]